| Study Number |
Title |
| 12278A |
Clinical Urology Research Screening Protocol
|
| 14578A |
A Phase I/II Study of E7389 Halichondrin B analog (NSC# 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
|
| 15550B |
Bladder Cancer Sample Collection
|
| 09-152-B |
CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cislpatin, and placebo in patients with Advanced transitional cell carcinoma
|
| 09-288-B |
Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
|
| 10-017-B |
A Phase I Open Label Single Center Exploratory Study of an Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Urinary Diversion Following Radical Cycstectomy
|
| 10-151-B |
Prospective Multi-Center Evaluation of High Grade T1 Bladder Cancer Protocol
|
| 11-0106 |
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
|
| 10-153-B |
Multi-institutional evaluation and quality of care initiative for the management of muscle invasive bladder cancer
|
| 11-0646 |
S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
|
| 11-0719 |
AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0980 ADMINISTERED ONCE DAILY IN PATIENTS WITH REFRACTORY SOLID TUMORS OR NON-HODGKIN�S LYMPHOMA
|
| 13-0311 |
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
|
Bone